Phenotypes associated with this allele

• Allele Symbol: Tg(MMTV-Myc)141-3Led
• Allele Name: transgene insertion 141-3, Philip Leder
• Allele ID: MGI:2447500
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Bin1^tm1Gcp/Bin1^tm2Gcp Tg(MMTV-Myc)141-3Led/0 Tg(Wap-cre)11738Mam/0	involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL	MGI:3697474
cx2	Cdc25a^tm1Kiyo/Cdc25a^+ Tg(MMTV-Myc)141-3Led/?	involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1	MGI:3718004
cx3	Tg(MMTV-Cdc37)1Stp/0 Tg(MMTV-Myc)141-3Led/0	involves: C57BL/6 * CD-1 * DBA/2 * FVB/N	MGI:3839909
cx4	Tg(MMTV-Myc)141-3Led/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0	involves: C57BL/6J * CD-1 * FVB/N	MGI:5827760
tg5	Tg(MMTV-Myc)141-3Led/0	involves: C57BL/6J * CD-1	MGI:3839911

Genotype
MGI:3697474

cn1

• Allelic Composition: Bin1^tm1Gcp/Bin1^tm2Gcp; Tg(MMTV-Myc)141-3Led/0; Tg(Wap-cre)11738Mam/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary adenocarcinoma incidence ( J:117330 )

increased lymphoma incidence ( J:117330 )

• some mice develop aggressive lymphomas which occasionally appear before mammary carcinomas

cellular

abnormal cell physiology ( J:117330 )

• tumor cells show increased motility in monolayer culture

decreased apoptosis ( J:117330 )

• tumor cells in culture show several fold greater resistance to serum deprivation-induced apoptosis

increased cell proliferation ( J:117330 )

• tumor cells show 3-4 fold higher rates of proliferation under anchorage-dependent conditions

homeostasis/metabolism

abnormal enzyme/coenzyme activity ( J:117330 )

• tumor cells have higher gelatinase activity

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:117330 )

integument

increased mammary adenocarcinoma incidence ( J:117330 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:117730

Genotype
MGI:3718004

cx2

• Allelic Composition: Cdc25a^tm1Kiyo/Cdc25a⁺; Tg(MMTV-Myc)141-3Led/?
• Genetic Background: involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1

neoplasm

neoplasm ( J:123144 )

N • tumorigenesis is similar to in Tg(MMTV-Myc)141-3Led transgenic mice

Genotype
MGI:3839909

cx3

• Allelic Composition: Tg(MMTV-Cdc37)1Stp/0; Tg(MMTV-Myc)141-3Led/0
• Genetic Background: involves: C57BL/6 * CD-1 * DBA/2 * FVB/N

neoplasm

increased tumor incidence ( J:62465 )

♀ • 50% of female mice develop tumors by 115 days compared to the same rate at 250 days in Tg(MMTV-Myc)141-3Led mice

♀ • females exhibit increased tumors per mouse compared to in Tg(MMTV-Myc)141-3Led mice

♀ • virgin females develop a wider spectrum of fast growing tumors compared to Tg(MMTV-Myc)141-3Led virgin females

increased salivary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

increased mammary gland tumor incidence ( J:62465 )

♀ • breeding females develop mammary ductal and alveolar adenocarcinomas

increased mammary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

increased Leydig cell tumor incidence ( J:62465 )

♂ • Leydig cell tumors in males as young as 10 months

increased lymphoma incidence ( J:62465 )

♀ • in virgin females

reproductive system

increased Leydig cell number ( J:62465 )

♂ • 75% of male mice exhibit Leydig cell hyperplasia at 400 days

increased Leydig cell tumor incidence ( J:62465 )

♂ • Leydig cell tumors in males as young as 10 months

endocrine/exocrine glands

increased salivary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

increased mammary gland tumor incidence ( J:62465 )

♀ • breeding females develop mammary ductal and alveolar adenocarcinomas

increased mammary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

increased Leydig cell number ( J:62465 )

♂ • 75% of male mice exhibit Leydig cell hyperplasia at 400 days

increased Leydig cell tumor incidence ( J:62465 )

♂ • Leydig cell tumors in males as young as 10 months

integument

increased mammary gland tumor incidence ( J:62465 )

♀ • breeding females develop mammary ductal and alveolar adenocarcinomas

increased mammary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

digestive/alimentary system

increased salivary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

craniofacial

increased salivary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

growth/size/body

increased salivary adenocarcinoma incidence ( J:62465 )

♀ • in virgin females

Genotype
MGI:5827760

cx4

• Allelic Composition: Tg(MMTV-Myc)141-3Led/0; Tg(MMTV-rtTA)1Lach/0; Tg(tetO-Kras2)12Hev/0
• Genetic Background: involves: C57BL/6J * CD-1 * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:133578 )

♀ • mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • mammary tumors develop after withdrawal of doxycycline at a median age of 33 weeks, indicating recurrent tumors

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

integument

increased mammary gland tumor incidence ( J:133578 )

♀ • mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • mammary tumors develop after withdrawal of doxycycline at a median age of 33 weeks, indicating recurrent tumors

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:133578 )

♀ • mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

♀ • removal of doxycycline results in apoptosis and reduced proliferation of tumors after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • after doxycycline withdrawal, almost all of the transformed mammary glands completely regress to a nonpalpable state, however, hyperplastic changes persist in the glands

♀ • mammary tumors develop after withdrawal of doxycycline at a median age of 33 weeks, indicating recurrent tumors

♀ • tumor recurrence is associated with reactivation of oncogenic transgenes and somatic mutations in the rtTA transgene

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:133578

Genotype
MGI:3839911

tg5

• Allelic Composition: Tg(MMTV-Myc)141-3Led/0
• Genetic Background: involves: C57BL/6J * CD-1

neoplasm

increased tumor incidence ( J:62465 )

♀ • female mice develop tumors as early as 3 months of age, and 50% of mice develop tumors by 250 days

increased B cell derived lymphoma incidence ( J:62465 )

♀ • in 25% of virgin females by 500 days

reproductive system

increased Leydig cell number ( J:62465 )

♂ • 20% of male mice exhibit Leydig cell hyperplasia at 400 days

endocrine/exocrine glands

increased Leydig cell number ( J:62465 )

♂ • 20% of male mice exhibit Leydig cell hyperplasia at 400 days